AUPH - חוב כולל להון Aurinia Corp

The change in the debt-to-equity ratio demonstrates the financial stability of Aurinia Pharmaceuticals (AUPH), whose immune therapy supplies are protected by flexible contracts. The company's revenues are based on the sale of a patented lupus nephritis drug through pharmacy chains. Production scaling relies on external contractors and strict SLA agreements, while 0.09 serves as the final level marker.

The total debt-to-equity ratio determines the extent of a business's reliance on borrowed funds relative to its own resources. This metric is calculated as the ratio of total liabilities to shareholders' equity, reflecting financial stability. Analyzing the current total debt-to-equity ratio allows for an assessment of bankruptcy risks or expansion potential. A decrease in this indicator confirms the autonomy of Aurinia Pharmaceuticals (AUPH). This is critical when scaling partnerships for the commercialization of lupus nephritis therapy.